<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921635</url>
  </required_header>
  <id_info>
    <org_study_id>ANZGOG0401</org_study_id>
    <secondary_id>TSGHIRB095-05-044</secondary_id>
    <nct_id>NCT00921635</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Impact of Maintaining Hemoglobin Levels in Anemic Patients With Carcinoma of the Cervix</brief_title>
  <acronym>HOSTT</acronym>
  <official_title>A Phase III Study to Evaluate the Impact of Maintaining Haemoglobin Levels Above 120g/L Verses Above 100g/L in Anaemic Patients With Carcinoma of the Cervix Receiving Concurrent Cisplatin and Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tri-Service General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility, safety and short term effects on
      health related quality of life, of maintaining hemoglobin from 120 to 130 g/L versus from 100
      to 110 g/L, with red cell concentrate (RCC) transfusion, in women having chemo-radiation for
      cancer of the cervix.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The impact of maintaining hemoglobin levels above 120 g/L versus above 100 g/L</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Maintain hemoglobin level above 120 g/L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemoglobin level from 120 g/L to 130 g/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintain hemoglobin level above 100 g/L</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hemoglobin level from 100 g/L to 110 g/L</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood transfusion</intervention_name>
    <description>Blood transfusion to maintain hemoglobin level above 120 g/L</description>
    <arm_group_label>Maintain hemoglobin level above 120 g/L</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood transfusion</intervention_name>
    <description>Blood transfusion to maintain hemoglobin level above 100 g/L</description>
    <arm_group_label>Maintain hemoglobin level above 100 g/L</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated cervix cancer

          -  FIGO stage IB2, II, IIIB, IVA

          -  Suitable for treatment with radical intent using concurrent cisplatin and pelvic
             radiation

        Exclusion Criteria:

          -  Hemoglobin level above 125g/L

          -  Lower one-third vaginal involvement

          -  Para-aortic lymphadenopathy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yee-Min Jen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Randiation Oncology</affiliation>
  </overall_official>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>June 18, 2009</last_update_submitted>
  <last_update_submitted_qc>June 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Yee-Min Jen/Head of the department of Radiation oncology</name_title>
    <organization>Radiation oncology of Tri-Service General Hospital</organization>
  </responsible_party>
  <keyword>Haemoglobin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

